Log in

Relevant bibliographies by topics / 5-Fluoruracil / Journal articles

To see the other types of publications on this topic, follow the link: 5-Fluoruracil.

Journal articles on the topic '5-Fluoruracil'

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '5-Fluoruracil.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hammond, Stephen T., Shannon K. Parr, Emma G. Hilgenfeld, Vanessa-Rose G. Turpin, and Carl J. Ade. "Microvascular Responses Following 5‐Fluoruracil Chemotherapy Administration." FASEB Journal 34, S1 (2020): 1. http://dx.doi.org/10.1096/fasebj.2020.34.s1.06985.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Martins, Carina Gomes, Sandrine Comparsi Wagner, and Rafael Linden. "Individualização Farmacocinética das Doses de 5-Fluoruracil no Câncer Colorretal." Revista Brasileira de Cancerologia 59, no. 2 (2013): 271–80. http://dx.doi.org/10.32635/2176-9745.rbc.2013v59n2.535.

Full text

Abstract:

Introdução: O 5-Fluoruracil (5-FU) é um antimetabólito amplamente utilizado no tratamento do câncer colorretal, com significativa variabilidade na resposta terapêutica e na ocorrência de toxicidade associada à sua farmacocinética variável. Objetivo: Revisar os aspectos clínicos e laboratoriais da individualização farmacocinética dos tratamentos com 5-FU em pacientes com cáncer colorretal. Método: Realizou-se uma revisão de literatura nas bases de dados PubMed, Periódicos Capes, SciElo, Medline e Bireme. Foram incluídos estudos publicados a partir de 1997, com as palavras-chave: 5-Fluoruracil;

APA, Harvard, Vancouver, ISO, and other styles

3

Ferrari, V. D., F. Valcamonico, V. Amoroso, et al. "FAFOXIRI: A phase II trial of an alternating regimen of irinotecan/5-fluoruracil/folinic acid and oxaliplatin/5-fluoruracil/folinic acid in metastatic colorectal cancer." Journal of Clinical Oncology 23, no. 16_suppl (2005): 3660. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3660.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mahoney, Sara E., J. Mark Davis, Jamie L. McClellan, Martin D. Carmichael, M. M. Pena, and E. Angela Murphy. "5-fluoruracil Chemotherapy Decreases Voluntary Physical Activity in C57BL/6 Mice." Medicine & Science in Sports & Exercise 43, Suppl 1 (2011): 904. http://dx.doi.org/10.1249/01.mss.0000402526.60262.48.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Perles, F., A. Gómez, M. R. González, J. J. Reina, J. L. Bayo, and A. Rodríguez. "Characteristics of intravenous continuous infusion of fluoruracil (5-FU) in ambulatory patients." European Journal of Cancer 37 (April 2001): S429. http://dx.doi.org/10.1016/s0959-8049(01)82042-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Diniz, Michelle dos Santos, Luiz Maurício Costa Almeida, Jackson Machado-Pinto, Marcos Felipe Fonseca Alves, and Maria Carolina Barbosa Alvares. "Nódulos reumatoides: avaliação comparativa da resposta terapêutica com triancinolona e fluoruracil intralesional." Anais Brasileiros de Dermatologia 86, no. 6 (2011): 1236–38. http://dx.doi.org/10.1590/s0365-05962011000600035.

Full text

Abstract:

Os nódulos reumatoides correspondem à manifestação extra-articular mais comum da artrite reumatoide, ocorrendo em cerca de 20-25% dos pacientes. A etiologia é desconhecida. Apesar de os nódulos poderem apresentar remissão espontânea durante o tratamento, eles, em geral, representam um desafio terapêutico. Apresenta-se um caso no qual se avaliou a resposta dos nódulos reumatoides por meio de ultrassonografia após infiltração de triancinolona e 5-fluoruracil.

APA, Harvard, Vancouver, ISO, and other styles

7

Lima, G. de M. G., M. C. Severo, G. de F. Santana-Melo, et al. "Amniotic membrane as a biological dressing for 5-fluoruracil-induced oral mucositis in rats." International Journal of Oral and Maxillofacial Surgery 44, no. 7 (2015): 845–51. http://dx.doi.org/10.1016/j.ijom.2015.01.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Petaccia, Manuela, Patrizia Gentili, Neva Bešker, et al. "Kinetics and mechanistic study of competitive inhibition of thymidine phosphorylase by 5-fluoruracil derivatives." Colloids and Surfaces B: Biointerfaces 140 (April 2016): 121–27. http://dx.doi.org/10.1016/j.colsurfb.2015.12.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jovtis, S., A. Marantz, E. Almira, et al. "Phase II trial of gemcitabine (GEM), 5-Fluoruracil (5-FU) and leucovorin (LV) in advanced pancreatic cancer (PC)." European Journal of Cancer 35 (September 1999): S157. http://dx.doi.org/10.1016/s0959-8049(99)81014-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Clark, Jeffrey, William Sikov, Frank Cummings, et al. "Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer." Journal of Cancer Research and Clinical Oncology 122, no. 9 (1996): 554–58. http://dx.doi.org/10.1007/bf01213552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Gonzalez, M. S., J. Rebollo, V. Escudero, et al. "Pharmacokinetic (pk) guide for dose adjustments in cancer patients (pts) treated with 5-fluoruracil (5-fu) infusions. Preliminary results." Journal of Clinical Oncology 26, no. 15_suppl (2008): 13550. http://dx.doi.org/10.1200/jco.2008.26.15_suppl.13550.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

PARROZZANI, R., E. PILOTTO, A. DARIO, G. MIGLIONICO, and E. MIDENA. "Combined topical 5-Fluoruracil and extensive surgery in the management of corneo-conjunctival squamous cell carcinoma." Acta Ophthalmologica 90 (August 6, 2012): 0. http://dx.doi.org/10.1111/j.1755-3768.2012.4665.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Muzzalupo, Rita, Fiore Pasquale Nicoletta, Sonia Trombino, Roberta Cassano, Francesca Iemma, and Nevio Picci. "A new crown ether as vesicular carrier for 5-fluoruracil: Synthesis, characterization and drug delivery evaluation." Colloids and Surfaces B: Biointerfaces 58, no. 2 (2007): 197–202. http://dx.doi.org/10.1016/j.colsurfb.2007.03.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Graziano, Sara, Mariolina Gullì, Elena Maestri, and Nelson Marmiroli. "The global effect of exposing bakers' yeast to 5-fluoruracil and nystatin; a view to Toxichip." Chemosphere 145 (February 2016): 470–79. http://dx.doi.org/10.1016/j.chemosphere.2015.11.045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Parrozzani, Raffaele, Luisa Frizziero, Sara Trainiti, et al. "Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study." British Journal of Ophthalmology 101, no. 8 (2016): 1094–99. http://dx.doi.org/10.1136/bjophthalmol-2016-309219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Gifoni, Markus, Roberto Cesar Lima, Aldo Angelo Moreira Lima, et al. "Clinical mucositis and intestinal permeability abnormalities in metastatic colorectal cancer patients treated with irinotecan and 5-fluoruracil." Journal of Clinical Oncology 30, no. 15_suppl (2012): e14183-e14183. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14183.

Full text

Abstract:

e14183 Background: The comprehension of the mechanisms involved in the adverse events of the cytotoxic drugs available to treat metastatic colorctal cancer (CRC) is necessary to improve their efficacy and safety. The irinotecan, fluoruracil and folinic acid (IFL) bolus regimen have as its major toxicity issue the complex and multi-mediated gastrointestinal mucositis. Nevertheless, it is difficult to obtain a reliable measurement of the intestinal abnormalities and functional consequences caused by intestinal mucositis, as almost all the clinical data available are reported on a patient symptom

APA, Harvard, Vancouver, ISO, and other styles

17

Song, Dianwen, Tong Meng, Wei Xu, et al. "5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis." Bone 78 (September 2015): 46–54. http://dx.doi.org/10.1016/j.bone.2015.04.047.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Pan, Ruijun, Wei Cai, Jing Sun, Chaoran Yu, Peiyong Li, and Minhua Zheng. "Inhibition of KHSRP sensitizes colorectal cancer to 5‐fluoruracil through miR‐501‐5p‐mediated ERRFI1 mRNA degradation." Journal of Cellular Physiology 235, no. 2 (2019): 1576–87. http://dx.doi.org/10.1002/jcp.29076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Menendez, Alvaro G., Daniel J. Curzake, LuGuang Luo, and Harold J. Wanebo. "C6-ceramide's effect on KRAS-defined colorectal cancer cells treated with oxaliplatin, 5-fluoruracil with and without cetuximab." Journal of Clinical Oncology 34, no. 4_suppl (2016): 619. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.619.

Full text

Abstract:

619 Background: Cetuximab (Cet) is beneficial for patients with metastatic KRAS Wild type (WT) colorectal cancer (mCRC) only. C6-Ceramide (C6-Cer) can act synergistically with chemotherapy to induce cancer cell death. The aim of this study was to compare growth inhibition percentage (GIP) of cytostatics 5-fluoruracil (5-FU), oxaliplatin (Ox) and Cet with or without C6-Cer in KRAS WT and KRAS mutant (KRAS Mut) CRC cell lines (SW48 and SW480, respectively). Methods: Both cell lines were incubated with IC50 concentrations of test drugs. Drug concentrations included 0.8µM for 5-FU, 0.04µM for Ox,

APA, Harvard, Vancouver, ISO, and other styles

20

Garrido-Laguna, Ignacio, María de la Luz Amador, Juan Ruiz, and Hernán Cortés-Funes. "Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer." Clinical and Translational Oncology 11, no. 3 (2009): 183–85. http://dx.doi.org/10.1007/s12094-009-0336-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Chilinqirova, N., V. Marinova, G. Kurteva, and D. Svinarov. "6120 POSTER Personalized Dose Management for 5-fluoruracil Based Chemotherapy Regimens to Lower Severe Toxicity by Cancer Patients." European Journal of Cancer 47 (September 2011): S428. http://dx.doi.org/10.1016/s0959-8049(11)71765-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Kim, Tae Won, Julien Taieb, Ellen B. Gurary, Nati Lerman, Karen Cui, and Takayuki Yoshino. "Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003." Future Oncology 17, no. 36 (2021): 5013–22. http://dx.doi.org/10.2217/fon-2021-0899.

Full text

Abstract:

Oxaliplatin-based chemotherapy with a regimen such as FOLFOX with or without targeted therapy is a standard of care option for advanced colorectal cancer; however, long-term exposure to oxaliplatin is associated with cumulative toxicity. Growing evidence suggests maintenance therapy with a less intensive regimen after platinum-based induction therapy can provide continuing benefit with reduced toxicity. We describe the rationale and design of the Phase III LYNK-003 trial, which will evaluate the efficacy and safety of olaparib with or without bevacizumab compared with 5-fluoruracil plus bevaci

APA, Harvard, Vancouver, ISO, and other styles

23

Mayr, Martina, Barbara Alberter, Karin Becker, Roland M. Schmid, and Matthias Philip Ebert. "Phase I study of imatinib, cisplatin, and fluoruracil in patients with advanced gastric cancer." Journal of Clinical Oncology 30, no. 4_suppl (2012): 115. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.115.

Full text

Abstract:

115 Background: Combination chemotherapies are established as standard treatment in gastric cancer, but prognosis remains poor. Integration of targeted therapies may provide an additional benefit. Imatinib may inhibit platelet derived growth factor (PDGF) mediated tumor growth and amplify effects of chemotherapy. This Phase I study evaluated dose limiting toxicity (DLT) of imatinib in combination with cisplatin and fluoruracil/ capecitabine therapy in gastric cancer. Methods: The study was designed as a 3-patient cohort dose-escalating trial. Patients (pts) received cisplatin (60 mg/m2 d1 q 21

APA, Harvard, Vancouver, ISO, and other styles

24

Umemoto, Terumasa, Michihiro Hashimoto, Takayoshi Matsumura, Ayako Nakamura-Ishizu, and Toshio Suda. "Ca2+–mitochondria axis drives cell division in hematopoietic stem cells." Journal of Experimental Medicine 215, no. 8 (2018): 2097–113. http://dx.doi.org/10.1084/jem.20180421.

Full text

Abstract:

Most of the hematopoietic stem cells (HSCs) within the bone marrow (BM) show quiescent state with a low mitochondrial membrane potential (ΔΨm). In contrast, upon stress hematopoiesis, HSCs actively start to divide. However, the underlying mechanism for the initiation of HSC division still remains unclear. To elucidate the mechanism underlying the transition of cell cycle state in HSCs, we analyzed the change of mitochondria in HSCs after BM suppression induced by 5-fluoruracil (5-FU). We found that HSCs initiate cell division after exhibiting enhanced ΔΨm as a result of increased intracellular

APA, Harvard, Vancouver, ISO, and other styles

25

Perboni, Simona, Cyril Bowers, Shinya Kojima, Akihiro Asakawa, and Akio Inui. "Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice." World Journal of Gastroenterology 14, no. 41 (2008): 6303. http://dx.doi.org/10.3748/wjg.14.6303.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ferreira, M., A. Quintela, A. Fernandes, J. Oliveira, A. Henriques, and J. Assis. "Chemotherapy (CT) with cisplatin (DDP) +continous 5 fluoruracil (5FUc) in the treatment of advanced anal squamous cell carcinoma (SCCa)." European Journal of Cancer 29 (January 1993): S104. http://dx.doi.org/10.1016/0959-8049(93)91184-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Saam, Jennifer, Gregory C. Critchfield, Stephanie A. Hamilton, Benjamin B. Roa, Richard J. Wenstrup, and Rajesh R. Kaldate. "Body Surface Area–based Dosing of 5-Fluoruracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens." Clinical Colorectal Cancer 10, no. 3 (2011): 203–6. http://dx.doi.org/10.1016/j.clcc.2011.03.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Shamrai, V. A., O. I. Misiurko, D. I. Grebeniuk, and I. V. Taran. "DYNAMICS OF CHANGES IN THE LEVELS OF MAIN FEMALE SEX HORMONES IN SERIAL APPLICATION OF 5-FLUORURACIL IN THE EXPERIMENT." Bulletin of Problems Biology and Medicine 4, no. 1 (2021): 209. http://dx.doi.org/10.29254/2077-4214-2021-4-162-209-213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Savarese, A., A. Felici, A. Micheli, et al. "Concomitant chemo-radiotherapy with continuous infusion cisplatin and 5-fluoruracil in locally advanced cervical carcinoma (LACC): A single institution experience." Journal of Clinical Oncology 22, no. 14_suppl (2004): 5073. http://dx.doi.org/10.1200/jco.2004.22.14_suppl.5073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Savarese, A., A. Felici, A. Micheli, et al. "Concomitant chemo-radiotherapy with continuous infusion cisplatin and 5-fluoruracil in locally advanced cervical carcinoma (LACC): A single institution experience." Journal of Clinical Oncology 22, no. 14_suppl (2004): 5073. http://dx.doi.org/10.1200/jco.2004.22.90140.5073.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kitago, Minoru, Osamu Itano, Masahiro Shinoda, et al. "Beneficial effects and long-term outcomes of neoadjuvant chemoradiotherapy with 5-fluoruracil, cisplatin, mitomycin C, and heparin for pancreatic cancer." Pancreatology 16, no. 4 (2016): S65. http://dx.doi.org/10.1016/j.pan.2016.06.236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Cantore, Maurizio, Giovanni Serio, Paolo Pederzoli, et al. "Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma." Cancer Chemotherapy and Pharmacology 58, no. 4 (2006): 504–8. http://dx.doi.org/10.1007/s00280-006-0200-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Machover, D., A. de Gramont, J. Gastiaburu, et al. "Phase II trial of oxaliplatin: L-OHP® in patients with colorectal carcinoma (CRC) previously resistant to 5 fluoruracil (5 FU) and folinic acid (FA)." European Journal of Cancer 29 (January 1993): S96. http://dx.doi.org/10.1016/0959-8049(93)91134-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Inselmann, G., Ute Holzlöhner, and H. T. Heidemann. "Effect of 5-Fluorocytosine and 5-Fluorouracil on Human and Rat Hepatic Cytochrome P 450 Die Wirkung von 5-Fluorcytosin und 5-Fluoruracil auf Leber-Cytochrom-P 450 in Mensch und Ratte." Mycoses 32, no. 12 (2009): 638–43. http://dx.doi.org/10.1111/j.1439-0507.1989.tb02196.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Pérez-Molina, Álvaro, Luisa M. Pastrana-Martínez, Lorena T. Pérez-Poyatos, Sergio Morales-Torres, and Francisco J. Maldonado-Hódar. "One-Pot Thermal Synthesis of g-C3N4/ZnO Composites for the Degradation of 5-Fluoruracil Cytostatic Drug under UV-LED Irradiation." Nanomaterials 12, no. 3 (2022): 340. http://dx.doi.org/10.3390/nano12030340.

Full text

Abstract:

Graphitic carbon nitride (g-C3N4) was used to enhance the photocatalytic activity of ZnO nanoparticles for the degradation of 5-fluorouracil (5-FU) cytostatic drug under UV-LED irradiation. CN/ZnO composites were synthetized by an easy one-pot thermal method, varying the g-C3N4 loading, i.e., from 10 to 67 wt% and a post-thermal exfoliation in air. The physicochemical and optical properties of the materials were analyzed by several techniques. CN/ZnO composites showed a coral-like structure of spherical ZnO wurtzite particles on the g-C3N4 structure. In general, the synergism and heterojunctio

APA, Harvard, Vancouver, ISO, and other styles

36

Graeven, Ullrich, K. Ridwelski, M. Manns, et al. "CPT-11 combined or alternated with 5 fluoruracil/folinic acid (5-FU/FA) vs mayo clinic regimen in first line therapy of advanced colorectal cancer (ACRC)." Gastroenterology 120, no. 5 (2001): A611. http://dx.doi.org/10.1016/s0016-5085(08)83037-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

GRAEVEN, U., K. RIDWELSKI, M. MANNS, et al. "CPT-11 combined or alternated with 5 fluoruracil/folinic acid (5-FU/FA) vs mayo clinic regimen in first line therapy of advanced colorectal cancer (ACRC)." Gastroenterology 120, no. 5 (2001): A611. http://dx.doi.org/10.1016/s0016-5085(01)83037-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Chen, W., C. Law, M. Chen, C. Chuang, and J. Hong. "A promising phase II trial of concurrent cisplatin, 5-fluoruracil, leucovorin and radiotherapy in the treatment of muscle invasive bladder cancer." International Journal of Radiation Oncology*Biology*Physics 54, no. 2 (2002): 279–80. http://dx.doi.org/10.1016/s0360-3016(02)03541-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Berger, D. P., H. H. Fiebig, J. R. Schmid, et al. "Dose response effects of adriamycin, cisplatin, mitomycin-C, 5-Fluoruracil, vepesid and vindesin on human tumor xenografts in the colony assay." Journal of Cancer Research and Clinical Oncology 111, S1 (1986): S51. http://dx.doi.org/10.1007/bf02579974.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Osipitan, Ositomiwa O., Yi Shi, and Anthony J. Di Pasqua. "Phenethyl Isothiocyanate-Containing Carbomer Gel for Use against Squamous Cell Carcinoma." Pharmaceutics 13, no. 1 (2021): 106. http://dx.doi.org/10.3390/pharmaceutics13010106.

Full text

Abstract:

It is currently estimated that one in every five Americans will develop skin cancer during their lifetime. Squamous cell carcinoma (SCC) is a common type of skin cancer that can develop due to the skin’s exposure to the sun. Herein, we prepared a topical gel containing 0.5% v/w phenethyl isothiocyanate (PEITC) for the treatment of SCC. PEITC is a naturally occurring isothiocyanate that has been shown to have efficacy against various types of cancer in preclinical studies. We first incorporated PEITC into a carbomer gel. A uniform formulation was prepared, and its viscosity was appropriate for

APA, Harvard, Vancouver, ISO, and other styles

41

Alam, Mohammad Mahboob, Abdulraheem SA Almalki, Thikryat Neamatallah, Nada M. Ali, Azizah M. Malebari, and Syed Nazreen. "Synthesis of New 1, 3, 4-Oxadiazole-Incorporated 1, 2, 3-Triazole Moieties as Potential Anticancer Agents Targeting Thymidylate Synthase and Their Docking Studies." Pharmaceuticals 13, no. 11 (2020): 390. http://dx.doi.org/10.3390/ph13110390.

Full text

Abstract:

Thymidylate synthase (TS) has emerged as a hot spot in cancer treatment, as it is directly involved in DNA synthesis. In the present article, nine hybrids containing 1,2,3-triazole and 1,3,4-oxadiazole moieties (6–14) were synthesized and evaluated for anticancer and in vitro thymidylate synthase activities. According to in silico pharmacokinetic studies, the synthesized hybrids exhibited good drug likeness properties and bioavailability. The cytotoxicity results indicated that compounds 12 and 13 exhibited remarkable inhibition on the tested Michigan Cancer Foundation (MCF-7) and Human colore

APA, Harvard, Vancouver, ISO, and other styles

42

Symeonidis, David G., Alexandros D. Liatsos, Evridiki K. Mazlimoglou, Eleni C. Geraki, and Christos Kosmas. "Posterior Reversible Encephalopathy Syndrome Associated with Oxaliplatin Use for Pancreatic Adenocarcinoma." Case Reports in Oncology 14, no. 2 (2021): 838–44. http://dx.doi.org/10.1159/000515076.

Full text

Abstract:

The posterior reversible encephalopathy syndrome (PRES) was first described by Hinchey’s group in 1996 as a reversible vasogenic brain edema on magnetic resonance imaging (MRI). Hypertension represents the most frequent manifestation associated with PRES. In the present report, we present a patient diagnosed with locally advanced pancreatic adenocarcinoma who received 3 cycles of a 5-fluoruracil plus oxaliplatin-based chemotherapy regimen and developed PRES after the third cycle. Several days after receiving the second cycle of FOLFOX chemotherapy, the patient started having episodes of hypert

APA, Harvard, Vancouver, ISO, and other styles

43

Suh, Byoung Jo. "A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Treated with Preoperative FOLFOX Chemotherapy Followed by Radical Subtotal Gastrectomy and D2 Lymph Node Dissection." Case Reports in Oncology 10, no. 1 (2017): 182–91. http://dx.doi.org/10.1159/000457791.

Full text

Abstract:

We report the case of a 73-year-old female who was diagnosed with advanced gastric cancer. Esophagogastroduodenoscopy was used to diagnose Borrmann type 3 advanced gastric cancer located at the gastric antrum. A biopsy revealed poorly differentiated adenocarcinoma. Abdominopelvic computed tomography (CT) and 18F-fluorodeoxyglucose positron emission tomography-CT (FDG-PET-CT) scans demonstrated multiple lymph node metastases, including the para-aortic lymph nodes. Systemic chemotherapy with 5-fluoruracil (5-FU), oxaliplatin, and leucovorin (FOLFOX) was initiated. An abdominopelvic CT scan taken

APA, Harvard, Vancouver, ISO, and other styles

44

Ruffo, Mariarosa, Ortensia Ilaria Parisi, Francesco Patitucci, et al. "Controlled Release of 5-FU from Chi–DHA Nanoparticles Synthetized with Ionic Gelation Technique: Evaluation of Release Profile Kinetics and Cytotoxicity Effect." Journal of Functional Biomaterials 11, no. 3 (2020): 48. http://dx.doi.org/10.3390/jfb11030048.

Full text

Abstract:

The ionic gelation technique allows us to obtain nanoparticles able to function as carriers for hydrophobic anticancer drugs, such as 5-fluoruracil (5-FU). In this study, reticulated chitosan– docosahexaenoic acid (Chi–DHAr) nanoparticles were synthesized by using a chemical reaction between amine groups of chitosan (Chi) and carboxylic acids of docosahexaenoic acid (DHA) and the presence of a link between Chi and DHA was confirmed by FT-IR, while the size and morphology of the obtained Chi-DHAr nanoparticles was evaluated with dynamic light scattering (DLS) and scanning electron microscopy (S

APA, Harvard, Vancouver, ISO, and other styles

45

Eickhoff, Axel S., Ralf Jakobs, and Juergen F. Riemann. "Retrospective trial of concurrent gemcitabine (GEM) or infusional 5-fluoruracil (5-FU), folinic acid (FA), interferon (IFN) treatment in patients with locally advanced or metastatic pancreatic adenocarcinoma." Gastroenterology 118, no. 4 (2000): A517. http://dx.doi.org/10.1016/s0016-5085(00)84196-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Giráldez, María Dolores, Juan José Lozano, Míriam Cuatrecasas, et al. "Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5′fluoruracil-based adjuvant chemotherapy." International Journal of Cancer 132, no. 5 (2012): 1090–97. http://dx.doi.org/10.1002/ijc.27747.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Paivana, Mavrikou, Kaltsas, and Kintzios. "Bioelectrical Analysis of Various Cancer Cell Types Immobilized in 3D Matrix and Cultured in 3D-Printed Well." Biosensors 9, no. 4 (2019): 136. http://dx.doi.org/10.3390/bios9040136.

Full text

Abstract:

Cancer cell lines are important tools for anticancer drug research and assessment. Impedance measurements can provide valuable information about cell viability in real time. This work presents the proof-of-concept development of a bioelectrical, impedance-based analysis technique applied to four adherent mammalian cancer cells lines immobilized in a three-dimensional (3D) calcium alginate hydrogel matrix, thus mimicking in vivo tissue conditions. Cells were treated with cytostatic agent5-fluoruracil (5-FU). The cell lines used in this study were SK-N-SH, HEK293, HeLa, and MCF-7. For each cell

APA, Harvard, Vancouver, ISO, and other styles

48

Germani, Marco Maria, and Roberto Moretto. "Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials." Cancers 14, no. 1 (2021): 52. http://dx.doi.org/10.3390/cancers14010052.

Full text

Abstract:

In metastatic colorectal cancer (mCRC), remarkable advances have been achieved with immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4, only in a small subset of tumours (4–5%), harbouring a deficient mismatch repair system (dMMR)/microsatellite instability–high (MSI-H) or mutations in the catalytic subunit of polymerase epsilon (POLE). Within this framework, several combination strategies have been investigated to sensitize proficient mismatch repair (pMMR)/microsatellite stable (MSS) mCRC to ICIs, with disappointing results so far. However, at the last ESMO meeting, two phas

APA, Harvard, Vancouver, ISO, and other styles

49

Zhao, Senlin, Tao Jiang, Huamei Tang, et al. "Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy." Journal of Gastroenterology and Hepatology 30, no. 4 (2015): 680–88. http://dx.doi.org/10.1111/jgh.12784.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lee, V. W. Y., R. Yao, E. Yip, K. Law, G. Tang, and K. R. Zhou. "Impact of Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens in the Management of Advanced Esophago-Gastric Cancer in Hong Kong." Value in Health 16, no. 7 (2013): A418. http://dx.doi.org/10.1016/j.jval.2013.08.544.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!